Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZB002 in Healthy Volunteers and Rheumatoid Arthritis
NCT05638854Phase 1Completed
- Sponsor
- Zenas BioPharma
- Start
- Dec 2022
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ZB002 in rheumatoid arthritis (RA) (2 arms), sponsored by Zenas BioPharma. Primary endpoint: Safety and Tolerability at Day 176. Started Dec 2022; status: completed.
02
Drugs
ZB002
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05638854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638854.